(Dual Agonist: GLP-1R / GIPR)

GLP-1T  is a synthetic dual incretin receptor agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This dual-pathway mechanism has been extensively investigated for its synergistic effects on glucose control, insulin sensitivity, lipid metabolism, and energy regulation in research models.

By combining the metabolic actions of both GLP-1 and GIP signaling, Tirzepatide represents an advanced next-generation incretin analog designed to explore multihormonal regulation of glucose and body-weight dynamics.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.

• GIPR activation: Supports insulin response and lipid metabolism while complementing GLP-1–mediated effects.

• Dual incretin synergy: Integrates complementary hormonal pathways to optimize metabolic outcomes.

• Energy expenditure modulation: Improves thermogenesis and fat oxidation in experimental settings.

• Cardiometabolic regulation: Demonstrates potential benefits on lipid profiles and inflammatory markers.

Potential Benefits (Based on Preclinical Research):

• Significant reduction in body-weight gain in obesity research models

• Improved insulin sensitivity and glucose tolerance

• Favorable effects on lipid metabolism and energy efficiency

• Enhanced appetite control and caloric balance

• Studied for applications in obesity, diabetes, and metabolic-syndrome research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

(Glucagon-Like Peptide-1 Receptor Agonist – GLP-1R)

GLP-1S is a synthetic long-acting analog of human glucagon-like peptide-1 (GLP-1), developed to mimic the activity of endogenous incretin hormones that regulate glucose metabolism and energy balance. By selectively binding to and activating the GLP-1 receptor (GLP-1R), Semaglutide enhances insulin secretion, suppresses glucagon release, and delays gastric emptying in research models.

Its extended half-life—achieved through structural modification that enhances albumin binding—makes Semaglutide a widely studied compound for metabolic, obesity, and glucose-regulation research as part of the incretin-based therapeutic class.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion while inhibiting glucagon release.

• Gastric motility modulation: Slows gastric emptying to prolong nutrient absorption and satiety.

• Appetite suppression: Engages central GLP-1R pathways in the hypothalamus, influencing hunger regulation.

• Metabolic efficiency: Promotes improved lipid metabolism and insulin sensitivity in experimental systems.

• Extended duration: Albumin-binding modification extends biological activity up to one week in vivo.

Potential Benefits (Based on Preclinical Research):

• Enhanced glucose control and insulin responsiveness

• Reduced food intake and body-weight modulation

• Improved lipid and energy metabolism markers

• Cardiometabolic protection observed in experimental models

• Studied for applications in metabolic, obesity, and endocrine research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

(Triple Agonist: GLP-1R / GIPR / GCGR)

GLP-1R is a synthetic triple-agonist peptide that simultaneously targets the receptors for glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR). This multi-receptor approach has been investigated for its ability to coordinate multiple hormonal axes that influence energy expenditure, glucose metabolism, and body-weight modulation in research models.

By integrating GLP-1, GIP, and glucagon signaling, Retatrutide represents a next-generation incretin-based compound studied for its broad metabolic and cardiometabolic potential in experimental systems.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Stimulates insulin secretion, slows gastric emptying, and reduces appetite through central and peripheral pathways.

• GIPR activation: Enhances glucose-stimulated insulin release and complements GLP-1 action for improved glycemic control.

• GCGR activation: Increases basal energy expenditure and promotes fat oxidation through mild glucagon receptor engagement.

• Triple-pathway synergy: Coordinates metabolic hormone signaling to enhance lipid utilization and energy balance beyond single-agonist mechanisms.

Potential Benefits (Based on Preclinical Research):

• Significant body-weight reductions in obesity research models

• Improved glucose regulation and insulin sensitivity

• Enhanced energy expenditure and lipid metabolism

• Favorable effects on cardiovascular and metabolic biomarkers

• Studied for potential in multi-incretin and metabolic-disease research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

(Triple Agonist: GLP-1R / GIPR / GCGR)

GLP-1-R is a novel synthetic peptide developed as a triple agonist targeting the receptors for glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR). This multi-receptor approach has been investigated in preclinical and clinical studies for its potential to enhance energy expenditure, improve glucose metabolism, and promote significant weight modulation in research models.

By simultaneously engaging these three metabolic pathways, Retatrutide has attracted scientific interest as a next-generation incretin-based therapeutic candidate in metabolic and obesity research.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Enhances insulin secretion, delays gastric emptying, and reduces appetite

• GIPR activation: Complements GLP-1 action, supporting insulin sensitivity and glucose regulation

• GCGR activation: Increases energy expenditure and promotes fat metabolism through mild glucagon signaling

• Integrates multiple hormonal axes to drive metabolic adaptations beyond single-pathway agonists

Potential Benefits (Based on Preclinical Research):

• Significant reductions in body weight in obesity research models

• Improved glycemic control and insulin sensitivity

• Enhanced energy expenditure and fat oxidation

• Studied for cardiometabolic benefits, including lipid regulation

• Potential applications in research exploring triple-incretin modulation

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

GLP-1R is a novel triple agonist peptide designed to activate the GLP-1, GIP, and glucagon receptors. This triagonist mechanism has shown promise in preclinical and clinical research for regulating appetite, enhancing energy expenditure, and promoting significant reductions in body weight and fat mass.

By simultaneously targeting multiple metabolic pathways, Retatrutide is being investigated for its potential in research models related to obesity, insulin resistance, and cardiometabolic health.

Mechanism of Action (Based on Preclinical and Early Clinical Research):

• GLP-1 Receptor Agonism: Slows gastric emptying and increases satiety

• GIP Receptor Agonism: Enhances insulin secretion and energy balance

• Glucagon Receptor Agonism: Increases energy expenditure and fat oxidation

Potential Benefits (Based on Research Studies):

• Significant weight loss through appetite suppression and increased fat metabolism

• Improved insulin sensitivity and glucose regulation

• Reduction in visceral and subcutaneous fat stores

• Enhanced cardiometabolic biomarkers in obesity models

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended strictly for laboratory research purposes.